A novel soft-tissue in vitro model for bisphosphonate-associated osteonecrosis

Fibrogenesis and Tissue Repair

Volumn 3, Issue 1, 2010, Pages

  Scheper, M A ^a   Chaisuparat, R ^b   Cullen, K J ^a   Meiller, T F ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^b CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; TETRAZOLIUM; ZOLEDRONIC ACID;

APOPTOSIS; ARTICLE; CELL DEATH; CELL LEVEL; CONCENTRATION RESPONSE; CONTROLLED STUDY; DENTIN; DRUG INDUCED DISEASE; DRUG RELEASE; FIBROBLAST; FLOW CYTOMETRY; GINGIVA; HUMAN; HUMAN CELL; IN VITRO STUDY; JAW OSTEONECROSIS; MOUTH MUCOSA;

EID: 79960412175     PISSN: None     EISSN: 17551536     Source Type: Journal    
DOI: 10.1186/1755-1536-3-6     Document Type: Article

References (47)

1. Cremers SC, Pillai G, Papapoulos SE. Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 2005, 44:551-570. 10.2165/00003088-200544060-00001, 15932344.
2. Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88:2961-2978. 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L, 10898340.
3. Rogers MJ, Watts DJ, Russell RG. Overview of bisphosphonates. Cancer 1997, 80:1652-1660. 10.1002/(SICI)1097-0142(19971015)80:8+<1652::AID-CNCR15>3.0.CO;2-Z, 9362432.
4. Civitelli R, Napoli N, Armamento-Villareal R. Use of intravenous bisphosphonates in osteoporosis. Curr Osteoporos Rep 2007, 5:8-13. 10.1007/BF02938617, 17320022.
5. Goffinet M, Thoulouzan M, Pradines A, Lajoie-Mazenc I, Weinbaum C, Faye JC, Seronie-Vivien S. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells. BMC Cancer 2006, 6:60. 10.1186/1471-2407-6-60, 1434759, 16539721.
6. Kanis JA. Bone and cancer: pathophysiology and treatment of metastases. Bone 1995, 17:101S-105S. 10.1016/8756-3282(95)00194-I, 8579890.
7. Mundy GR. Bone resorption and turnover in health and disease. Bone 1987, 8(Suppl 1):S9-16.
8. Cohen SB. An update on bisphosphonates. Curr Rheumatol Rep 2004, 6:59-65. 10.1007/s11926-004-0084-2, 14713403.
9. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 2003, 61:1115-1117. 10.1016/S0278-2391(03)00720-1, 12966493.
10. Olson KB, Hellie CM, Pienta KJ. Osteonecrosis of jaw in patient with hormone-refractory prostate cancer treated with zoledronic acid. Urology 2005, 66:658. 10.1016/j.urology.2005.03.028, 16140106.
11. Santini D, Vespasiani Gentilucci U, Vincenzi B, Picardi A, Vasaturo F, La Cesa A, Onori N, Scarpa S, Tonini G. The antineoplastic role of bisphosphonates: from basic research to clinical evidence. Ann Oncol 2003, 14:1468-1476. 10.1093/annonc/mdg401, 14504045.
12. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002, 302:1055-1061. 10.1124/jpet.102.035295, 12183663.
13. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 2006, 24:945-952. 10.1200/JCO.2005.04.2465, 16484704.
14. Bagan JV, Jimenez Y, Murillo J, Hernandez S, Poveda R, Sanchis JM, Diaz JM, Scully C. Jaw osteonecrosis associated with bisphosphonates: multiple exposed areas and its relationship to teeth extractions. Study of 20 cases. Oral Oncol 2006, 42:327-329. 10.1016/j.oraloncology.2005.08.001, 16275156.
15. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Papadimitriou C, Terpos E, Dimopoulos MA. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 2005, 23:8580-8587. 10.1200/JCO.2005.02.8670, 16314620.
16. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E, . American Society for Bone and Mineral Research Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2007, 22:1479-1491. 10.1359/jbmr.0707onj, 17663640, American Society for Bone and Mineral Research.
17. Mavrokokki T, Cheng A, Stein B, Goss A. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 2007, 65:415-423. 10.1016/j.joms.2006.10.061, 17307586.
18. Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006, 144:753-761.
19. Aragon-Ching JB, Ning YM, Chen CC, Latham L, Guadagnini JP, Gulley JL, Arlen PM, Wright JJ, Parnes H, Figg WD, Dahut WL. Higher incidence of osteonecrosis of the jaw (ONJ) in patients with metastatic castration resistant prostate cancer treated with anti-angiogenic agents. Cancer Invest 2009, 27:221-226. 10.1080/07357900802208608, 2648132, 19235596.
20. Boonyapakorn T, Schirmer I, Reichart PA, Sturm I, Massenkeil G. Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies. Oral Oncol 2008, 44:857-869. 10.1016/j.oraloncology.2007.11.012, 18282788.
21. Walter C, Al-Nawas B, Grotz KA, Thomas C, Thuroff JW, Zinser V, Gamm H, Beck J, Wagner W. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008, 54:1066-1072. 10.1016/j.eururo.2008.06.070, 18602738.
22. Fleisch H. Bisphosphonates in osteoporosis. Eur Spine J 2003, 12(Suppl 2):S142-146. 10.1007/s00586-003-0622-z, 13680318.
23. Bilezikian JP. Osteonecrosis of the jaw-do bisphosphonates pose a risk?. N Engl J Med 2006, 355:2278-2281. 10.1056/NEJMp068157, 17135582.
24. Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A. Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 2002, 42:1228-1236. 10.1177/009127002762491316, 12412821.
25. Coxon JP, Oades GM, Kirby RS, Colston KW. Zoledronic acid induces apoptosis and inhibits adhesion to mineralized matrix in prostate cancer cells via inhibition of protein prenylation. BJU Int 2004, 94:164-170. 10.1111/j.1464-4096.2004.04831.x, 15217454.
26. Skerjanec A, Berenson J, Hsu C, Major P, Miller WH, Ravera C, Schran H, Seaman J, Waldmeier F. The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function. J Clin Pharmacol 2003, 43:154-162. 10.1177/0091270002239824, 12616668.
27. Smith MR. Antitumor activity of bisphosphonates. Clin Cancer Res 2003, 9:5433-5434.
28. Scheper MA, Badros A, Salama AR, Warburton G, Cullen KJ, Weikel DS, Meiller TF. A novel bioassay model to determine clinically significant bisphosphonate levels. Support Care Cancer 2009, 17:1553-7. 10.1007/s00520-009-0710-7, 19653010.
29. Agis H, Blei J, Watzek G, Gruber R. Is zoledronate toxic to human periodontal fibroblasts?. J Dent Res 2010, 89:40-45. 10.1177/0022034509354298, 19948943.
30. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, Zervas K, Baer MR, Meiller T, Dimopoulos MA. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. J Clin Oncol 2008, 26:5904-5909. 10.1200/JCO.2008.16.9300, 19018084.
31. Reid IR, Bolland MJ, Grey AB. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity?. Bone 2007, 41:318-320. 10.1016/j.bone.2007.04.196, 17572168.
32. Scheper MA, Badros A, Chaisuparat R, Cullen KJ, Meiller TF. Effect of zoledronic acid on oral fibroblasts and epithelial cells: a potential mechanism of bisphosphonate-associated osteonecrosis. Br J Haematol 2009, 144:667-676. 10.1111/j.1365-2141.2008.07504.x, 2739302, 19036117.
33. Ruggiero SL, Drew SJ. Osteonecrosis of the jaws and bisphosphonate therapy. J Dent Res 2007, 86:1013-1021. 10.1177/154405910708601101, 17959890.
34. Farrugia MC, Summerlin DJ, Krowiak E, Huntley T, Freeman S, Borrowdale R, Tomich C. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope 2006, 116:115-120. 10.1097/01.mlg.0000187398.51857.3c, 16481822.
35. Bukowski JF, Dascher CC, Das H. Alternative bisphosphonate targets and mechanisms of action. Biochem Biophys Res Commun 2005, 328:746-750. 10.1016/j.bbrc.2004.11.075, 15694409.
36. Sedghizadeh PP, Kumar SK, Gorur A, Schaudinn C, Shuler CF, Costerton JW. Identification of microbial biofilms in osteonecrosis of the jaws secondary to bisphosphonate therapy. J Oral Maxillofac Surg 2008, 66:767-775. 10.1016/j.joms.2007.11.035, 18355603.
37. McGuigan JA, Kay JW, Elder HY. Critical review of the methods used to measure the apparent dissociation constant and ligand purity in Ca2+ and Mg2+ buffer solutions. Prog Biophys Mol Biol 2006, 92:333-370. 10.1016/j.pbiomolbio.2006.05.001, 16887174.
38. Herbozo PJ, Briones DL, Ferres AJ, Torrealba RL. Severe spontaneous cases of bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 2007, 65:1650-1654. 10.1016/j.joms.2007.03.021, 17656297.
39. Jeffcoat M, Watts NB. Osteonecrosis of the jaw: balancing the benefits and risks of oral bisphosphonate treatment for osteoporosis. Gen Dent 2008, 56:96-102. quiz 103-104, 111-102.
40. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA. Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 2007, 62:148-152. 10.1016/j.critrevonc.2006.12.005, 17336086.
41. Landesberg R, Cozin M, Cremers S, Woo V, Kousteni S, Sinha S, Garrett-Sinha L, Raghavan S. Inhibition of oral mucosal cell wound healing by bisphosphonates. J Oral Maxillofac Surg 2008, 66:839-847. 10.1016/j.joms.2008.01.026, 2426967, 18423269.
42. Ottewell PD, Woodward JK, Lefley DV, Evans CA, Coleman RE, Holen I. Anticancer mechanisms of doxorubicin and zoledronic acid in breast cancer tumor growth in bone. Mol Cancer Ther 2009, 8:2821-2832. 10.1158/1535-7163.MCT-09-0462, 19789217.
43. Guenther A, Gordon S, Tiemann M, Burger R, Bakker F, Green JR, Baum W, Roelofs AJ, Rogers MJ, Gramatzki M. The bisphosphonate zoledronic acid has antimyeloma activity in vivo by inhibition of protein prenylation. Int J Cancer 2010, 126:239-246. 10.1002/ijc.24758, 19621390.
44. Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli UA, Baran Y, Uslu R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biol Int 2009, 33:239-246. 10.1016/j.cellbi.2008.11.011, 19103299.
45. Ebert R, Zeck S, Krug R, Meissner-Weigl J, Schneider D, Seefried L, Eulert J, Jakob F. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone 2009, 44:858-864. 10.1016/j.bone.2009.01.009, 19442618.
46. Sutherland KA, Rogers HL, Tosh D, Rogers MJ. RANKL increases the level of Mcl-1 in osteoclasts and reduces bisphosphonate-induced osteoclast apoptosis in vitro. Arthritis Res Ther 2009, 11:R58. 10.1186/ar2681, 2688211, 19405951.
47. Jefferson KK, Goldmann DA, Pier GB. Use of confocal microscopy to analyze the rate of vancomycin penetration through Staphylococcus aureus biofilms. Antimicrob Agents Chemother 2005, 49:2467-2473. 10.1128/AAC.49.6.2467-2473.2005, 1140491, 15917548.